On November 6, 2025, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology ...

Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated safety and efficacy ...

BOOST Pharma ApS, a clinical-stage biopharmaceutical company focused on developing novel cell therapies for rare skeletal pediatric diseases, today announced that Sound Bioventures has joined its ...

The presentation will provide two-year follow-up data from the landmark BOOSTB4 Phase I/II clinical study. Notably, the results demonstrate that more than 50% of the treated patients experienced zero ...

If you’re trying to conceive, learning about fertilisation makes the process less of a mystery. It highlights that conception ...

Only two days after Bridgebio Pharma Inc. impressed investors with data from BBP-418 in limb-girdle muscular dystrophy type 2I/R9, the company was back at it again, this time reporting positive ...

Dyne Therapeutics, Inc. ((DYN)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, ...

The bridge aims to prevent the extinction of local mountain lions by allowing them to breed with other populations.

Beam Therapeutics Inc. trades at a relatively cheap valuation based on its multiples and potential in SCD. Learn more about ...

Decades ago, India’s tigers were on the brink of extinction. Slowly, their numbers have rebounded. But that ecological success has prompted a dire problem—and a race to save many of them from genetic ...